US 11,986,526 B2
Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC)
Alyssa M. Larson, Dana Point, CA (US); Kevin Love, Boston, MA (US); Alisha K. Weight, Mill Creek, WA (US); Alan Crane, Waban, MA (US); Robert S. Langer, Newton, MA (US); and Alexander M. Klibanov, Boston, MA (US)
Assigned to Eagle Biologics, Inc., Woodcliff Lake, NJ (US)
Filed by Eagle Biologics, Inc., Woodcliff Lake, NJ (US)
Filed on Oct. 19, 2020, as Appl. No. 17/073,618.
Application 17/073,618 is a continuation of application No. 15/809,602, filed on Nov. 10, 2017, granted, now 10,821,183.
Application 15/809,602 is a continuation of application No. 14/484,053, filed on Sep. 11, 2014, granted, now 9,833,513, issued on Dec. 5, 2017.
Claims priority of provisional application 62/030,521, filed on Jul. 29, 2014.
Claims priority of provisional application 62/026,497, filed on Jul. 18, 2014.
Claims priority of provisional application 62/008,050, filed on Jun. 5, 2014.
Claims priority of provisional application 61/988,005, filed on May 2, 2014.
Claims priority of provisional application 61/946,436, filed on Feb. 28, 2014.
Claims priority of provisional application 61/943,197, filed on Feb. 21, 2014.
Claims priority of provisional application 61/940,227, filed on Feb. 14, 2014.
Claims priority of provisional application 61/876,621, filed on Sep. 11, 2013.
Prior Publication US 2021/0030877 A1, Feb. 4, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 47/06 (2006.01); A61K 47/20 (2006.01); A61K 47/22 (2006.01); A61K 47/24 (2006.01); C07K 16/22 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); A61K 38/00 (2006.01)
CPC A61K 47/06 (2013.01) [A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 39/3955 (2013.01); A61K 47/20 (2013.01); A61K 47/22 (2013.01); A61K 47/24 (2013.01); C07K 16/22 (2013.01); C07K 16/241 (2013.01); C07K 16/2839 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/32 (2013.01); A61K 38/00 (2013.01)] 24 Claims
 
1. A liquid pharmaceutical formulation for injection comprising:
(i) an antibody;
(ii) about 0.1 M to about 0.4 M of 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC) or a pharmaceutically acceptable salt thereof; and
(iii) a pharmaceutically acceptable solvent;
wherein the liquid pharmaceutical formulation, when in a volume suitable for injection, has an absolute viscosity of from about 1 cP to about 100 cP at 25° C. as measured using a cone and plate viscometer or a microfluidic viscometer; and the absolute viscosity of the liquid pharmaceutical formulation is less than an absolute viscosity of a control composition comprising the antibody and the pharmaceutically acceptable solvent but without the EMMC; and
wherein the absolute viscosity is an extrapolated zero-shear viscosity.